Status:
TERMINATED
GIST and Memory and Attention Adaptation Training
Lead Sponsor:
University of Pittsburgh
Conditions:
GIST, Malignant
CBT
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Cognitive-behavioral therapy (CBT) has been found to be efficacious in the treatment of cancer-related cognitive impairment (CRCI). Memory and Attention Adaptation Training (MAAT) has been evaluated i...
Detailed Description
This study is a single-group, repeated measures (pre-post-intervention) design. This low-cost, simple design is intended to gather pilot data to gain an understanding of preliminary MAAT efficacy in t...
Eligibility Criteria
Inclusion
- Age 18 and above;
- Diagnosis of Gastrointestinal stromal tumor (GIST);
- At least 1 year post-initiation of TKI therapy;
- Report cognitive problems of memory and concentration attributed to GIST and/or treatment with a score of 10 or below on the FACT-Cog Impact on Quality of Life Scale;
- Able to speak and read English;
- Able to provide IRB-approved written informed consent; and
- Willingness to use videoconferencing and complete phone-based neurocognitive assessments
Exclusion
- Previous treatment with a tyrosine kinase inhibitor medication for a non-GIST diagnosis
- Previous CNS radiation, intrathecal therapy, or CNS-involved surgery;
- Previous cancer history with the exception of non-melanoma skin cancer;
- Previous exposure to chemotherapy with another cancer or due to other medical condition (e.g., methotrexate exposure for treatment of rheumatoid arthritis);
- Scoring 3 or below on the 6-item cognitive screen designed to detect severe memory disorders;1
- Significant neurodevelopmental, neurobehavioral, or medical risk factors likely to affect cognitive functioning (e.g., history of neurological disorder, stroke, traumatic brain injury greater than mild severity, such as loss of consciousness \>30 minutes, medical disorder that is unstable or likely to affect cognition such as metabolic disorder, heart attack, uncontrolled diabetes or endocrine dysfunction);
- Current severe DSM-5 mental disorder criteria, including but not limited to neurodevelopmental, substance abuse, mood, anxiety, or psychotic disorders
Key Trial Info
Start Date :
January 12 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 4 2022
Estimated Enrollment :
2 Patients enrolled
Trial Details
Trial ID
NCT04879979
Start Date
January 12 2021
End Date
May 4 2022
Last Update
July 16 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
UPMC Hillman Cancer Center
Pittsburgh, Pennsylvania, United States, 15232